Basic Information
RNALocate ID: | RLID:11000662 |
RNA Symbol: | hsa-miR-15a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-15a |
RNA ID: | miRBase:MIMAT0000068 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 24130905 |
Tissue/Cell Line: | Plasma |
Method: | qPCR |
Enrichment in expression of various miRNA species in the ExoQuick-precipitated fraction (“Exosomal fraction”) compared with the ExoQuick-depleted fraction (“Exosome-free fraction”) of the same pre-operative plasma samples from patients with lung SCC. Originally published in PLoS One. Aushev VN, et al, 2013. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | To this end, the exosomal fraction of the plasma from the lung SCC patients was precipitated by ExoQuick reagent and examined for miRNA levels using the same qPCR approach. We found that the ExoQuick-precipitated fraction was dramatically enriched with most species of miRNAs (Figure 3). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001249 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001250 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001251 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001252 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001253 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001254 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000655 | Exosome | Serum | 18589210 |
RLID:11000656 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000657 | Exosome | Renal cancer cells | 21670082 |
RLID:11000658 | Exosome | Breast milk | 22211110 |
RLID:11000659 | Exosome | Brain tissue | 23382797 |
RLID:11000660 | Exosome | Plasma | 23663360 |
RLID:11000661 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000663 | Exosome | Serum | 25349172 |
RLID:11000664 | Microvesicle | Plasma | 23077538 |
RLID:11000665 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000666 | Microvesicle | Hepatoma cells | 23771658 |
RLID:11005565 | Exosome | Peripheral blood | 32785072 |
RLID-D:11000007 | Exosome | Blood|B lymphoblastoid cells|Endothelial cells|Lymphoma tissue|Mast cells | |
RLID-D:11000267 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-15a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18022 |
MNDR | hsa-miR-15a-5p | Polycystic liver disease | MNDR-E-MI-18023 |
MNDR | hsa-miR-15a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18024 |
MNDR | hsa-miR-15a-5p | Peripheral arterial disease | MNDR-E-MI-18025 |
MNDR | hsa-miR-15a-5p | Oral squamous cell carcinoma | MNDR-E-MI-18026 |
MNDR | hsa-miR-15a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18027 |
MNDR | hsa-miR-15a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18028 |
MNDR | hsa-miR-15a-5p | Lymphoma | MNDR-E-MI-18029 |
MNDR | hsa-miR-15a-5p | Lymphoma non-hodgkin | MNDR-E-MI-18030 |
MNDR | hsa-miR-15a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18031 |
MNDR | hsa-miR-15a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18032 |
MNDR | hsa-miR-15a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18033 |
MNDR | hsa-miR-15a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18034 |
MNDR | hsa-miR-15a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18035 |
MNDR | hsa-miR-15a-5p | Triple negative breast cancer | MNDR-E-MI-18036 |
MNDR | hsa-miR-15a-5p | Acute promyelocytic leukemia | MNDR-E-MI-18037 |
MNDR | hsa-miR-15a-5p | Breast cancer luminal | MNDR-E-MI-18038 |
MNDR | hsa-miR-15a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-18039 |
MNDR | hsa-miR-15a-5p | Prostate cancer | MNDR-E-MI-18040 |
MNDR | hsa-miR-15a-5p | B-cell chronic lymphocytic leukemia | MNDR-E-MI-18041 |
MNDR | hsa-miR-15a-5p | Gastric cancer | MNDR-E-MI-18042 |
MNDR | hsa-miR-15a-5p | Gastric lymphoma | MNDR-E-MI-18043 |
MNDR | hsa-miR-15a-5p | Alzheimer disease | MNDR-E-MI-18044 |
MNDR | hsa-miR-15a-5p | Intracranial aneurysm | MNDR-E-MI-18045 |
MNDR | hsa-miR-15a-5p | Esophageal carcinoma | MNDR-E-MI-18046 |
MNDR | hsa-miR-15a-5p | Dysautonomia familial | MNDR-E-MI-18047 |
MNDR | hsa-miR-15a-5p | Seizures | MNDR-E-MI-18048 |
MNDR | hsa-miR-15a-5p | Huntington disease | MNDR-E-MI-18049 |
MNDR | hsa-miR-15a-5p | Chorea | MNDR-E-MI-18050 |
MNDR | hsa-miR-15a-5p | Cardiovascular disease | MNDR-E-MI-18051 |
MNDR | hsa-miR-15a-5p | Moyamoya disease | MNDR-E-MI-18052 |
MNDR | hsa-miR-15a-5p | Lung cancer | MNDR-E-MI-18053 |
MNDR | hsa-miR-15a-5p | Endometrial cancer | MNDR-E-MI-18054 |
MNDR | hsa-miR-15a-5p | Fragile x syndrome | MNDR-E-MI-18055 |
MNDR | hsa-miR-15a-5p | Parkinson disease | MNDR-E-MI-18056 |
MNDR | hsa-miR-15a-5p | Basal-like breast cancer | MNDR-E-MI-18057 |
MNDR | hsa-miR-15a-5p | Pituitary neoplasms | MNDR-E-MI-18058 |
MNDR | hsa-miR-15a-5p | Pancreatic cancer | MNDR-E-MI-18059 |
MNDR | hsa-miR-15a-5p | Malignant melanoma | MNDR-E-MI-18060 |
MNDR | hsa-miR-15a-5p | Gaucher disease | MNDR-E-MI-18061 |
MNDR | hsa-miR-15a-5p | Rectum adenocarcinoma | MNDR-E-MI-18062 |
MNDR | hsa-miR-15a-5p | Nephroblastoma | MNDR-E-MI-18063 |
MNDR | hsa-miR-15a-5p | Colon cancer | MNDR-E-MI-18064 |
MNDR | hsa-miR-15a-5p | Colon adenocarcinoma | MNDR-E-MI-18065 |
MNDR | hsa-miR-15a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18066 |
MNDR | hsa-miR-15a-5p | Familial ovarian cancer | MNDR-E-MI-18067 |
MNDR | hsa-miR-15a-5p | Prostate adenocarcinoma | MNDR-E-MI-18068 |
MNDR | hsa-miR-15a-5p | Kidney cancer | MNDR-E-MI-18069 |
MNDR | hsa-miR-15a-5p | Carcinoma ductal breast | MNDR-E-MI-18070 |
MNDR | hsa-miR-15a-5p | Glioblastoma | MNDR-E-MI-18071 |
MNDR | hsa-miR-15a-5p | Astrocytoma | MNDR-E-MI-18072 |
MNDR | hsa-miR-15a-5p | Glioma | MNDR-E-MI-18073 |
MNDR | hsa-miR-15a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-18074 |
MNDR | hsa-miR-15a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18075 |
MNDR | hsa-miR-15a-5p | Osteosarcoma | MNDR-E-MI-18076 |
MNDR | hsa-miR-15a-5p | Liposarcoma | MNDR-E-MI-18077 |
MNDR | hsa-miR-15a-5p | Infarction middle cerebral artery | MNDR-E-MI-18078 |
MNDR | hsa-miR-15a-5p | Meningioma | MNDR-E-MI-18079 |
MNDR | hsa-miR-15a-5p | Liver cancer | MNDR-E-MI-18080 |
MNDR | hsa-miR-15a-5p | Gastric adenocarcinoma | MNDR-E-MI-18081 |
MNDR | hsa-miR-15a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18082 |
MNDR | hsa-miR-15a-5p | Pituitary adenoma | MNDR-E-MI-18083 |
MNDR | hsa-miR-15a-5p | Lung squamous cell carcinoma | MNDR-E-MI-18084 |
MNDR | hsa-miR-15a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-18085 |
MNDR | hsa-miR-15a-5p | Lung adenocarcinoma | MNDR-E-MI-18086 |
MNDR | hsa-miR-15a-5p | Thyroid carcinoma | MNDR-E-MI-18087 |
MNDR | hsa-miR-15a-5p | Papillary thyroid carcinoma | MNDR-E-MI-18088 |
MNDR | hsa-miR-15a-5p | Ovarian carcinoma | MNDR-E-MI-18089 |
MNDR | hsa-miR-15a-5p | Bladder urothelial carcinoma | MNDR-E-MI-18090 |
MNDR | hsa-miR-15a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18091 |
MNDR | hsa-miR-15a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18092 |
MNDR | hsa-miR-15a-5p | Carcinoma renal cell | MNDR-E-MI-18093 |
MNDR | hsa-miR-15a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18094 |
MNDR | hsa-miR-15a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18095 |
MNDR | hsa-miR-15a-5p | Large cell carcinoma | MNDR-E-MI-18096 |
MNDR | hsa-miR-15a-5p | Cholangiocarcinoma | MNDR-E-MI-18097 |
MNDR | hsa-miR-15a-5p | Esophageal cancer | MNDR-E-MI-18098 |
MNDR | hsa-miR-15a-5p | Oncocytoma | MNDR-E-MI-18099 |
MNDR | hsa-miR-15a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18100 |
MNDR | hsa-miR-15a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-18101 |
MNDR | hsa-miR-15a-5p | Acute t cell leukemia | MNDR-E-MI-18102 |
MNDR | hsa-miR-15a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18103 |
MNDR | hsa-miR-15a-5p | Breast invasive carcinoma | MNDR-E-MI-18104 |
MNDR | hsa-miR-15a-5p | Hepatocellular carcinoma | MNDR-E-MI-18105 |
MNDR | hsa-miR-15a-5p | Familiar ovarian carcinoma | MNDR-E-MI-18106 |
MNDR | hsa-miR-15a-5p | B-cell lymphoma | MNDR-E-MI-18107 |
MNDR | hsa-miR-15a-5p | Rheumatoid arthritis | MNDR-E-MI-18108 |
MNDR | hsa-miR-15a-5p | T-cell leukemia | MNDR-E-MI-18109 |
MNDR | hsa-miR-15a-5p | Abdominal aortic aneurysm | MNDR-E-MI-18110 |
MNDR | hsa-miR-15a-5p | Chronic myelogenous leukemia | MNDR-E-MI-18111 |
MNDR | hsa-miR-15a-5p | Hodgkin lymphoma | MNDR-E-MI-18112 |
MNDR | hsa-miR-15a-5p | Burkitt lymphoma | MNDR-E-MI-18113 |
MNDR | hsa-miR-15a-5p | Myeloid leukemia | MNDR-E-MI-18114 |
MNDR | hsa-miR-15a-5p | Neuromyelitis optica | MNDR-E-MI-18115 |
MNDR | hsa-miR-15a-5p | Acute myelogenous leukemia | MNDR-E-MI-18116 |
MNDR | hsa-miR-15a-5p | Colorectal cancer | MNDR-E-MI-18117 |
MNDR | hsa-miR-15a-5p | Nasopharynx carcinoma | MNDR-E-MI-18118 |
MNDR | hsa-miR-15a-5p | Tyrosinemias | MNDR-E-MI-18119 |
MNDR | hsa-miR-15a-5p | Multiple myeloma | MNDR-E-MI-18120 |
MNDR | hsa-miR-15a-5p | Acute lymphocytic leukemia | MNDR-E-MI-18121 |
MNDR | hsa-miR-15a-5p | Ependymoma | MNDR-E-MI-18122 |
MNDR | hsa-miR-15a-5p | Nasopharyngeal cancer | MNDR-E-MI-18123 |
MNDR | hsa-miR-15a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-18124 |
MNDR | hsa-miR-15a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-18125 |
MNDR | hsa-miR-15a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-18126 |
MNDR | hsa-miR-15a-5p | Pituitary acth hypersecretion | MNDR-E-MI-18127 |
MNDR | hsa-miR-15a-5p | Stroke lacunar | MNDR-E-MI-18128 |
MNDR | hsa-miR-15a-5p | Breast cancer her3+ negative | MNDR-E-MI-18129 |
MNDR | hsa-miR-15a-5p | Low grade dysplastic nodule | MNDR-E-MI-18130 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAMTS5 | Homo sapiens | RR00042323 |
TOP